«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2022年06期

页码:

806-809

栏目:

论著

出版日期:

2022-12-20

文章信息/Info

Title:

Clinical observation of Maxingshigan decoction combined with methylprednisolone on PD-1 inhibitor-induced immune pneumonia

作者:

褚代芳¹; 张海涛¹; 金发光¹; 安琦²

710038 西安,空军军医大学唐都医院呼吸与危重症医学科¹、临床技能中心²

Author(s):

Chu Daifang¹;  Zhang Haitao¹;  Jin Faguang¹;  An Qi².

(¹Department of Respiratory and Critical Care Medicine; ²Clinical Technical Center, the Second Affiliated Hospital of Air Force Medical University, Xi'an710038, China)

关键词:

麻杏石甘汤;  甲泼尼龙;  免疫性肺炎

Keywords:

Ma Xing Shi Gan decoction;  Methylprednisolone;  Immune pneumonia

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2022.06.008

摘要:

目的 检查点抑制剂肺炎(checkpoint inhibitor pneumonitis, CIP)在亚洲人群中多发且致死率高,为寻找高效治疗方案,本文采用麻杏石甘汤联合甲泼尼龙对PD-1抑制剂所致的癌症患者免疫性肺炎(immune pneumonia)的影响。方法 将35例免疫性肺炎的癌症患者随机分为两组,对照组18例采用甲泼尼龙治疗,观察组17例给予麻杏石甘汤联合甲泼尼龙治疗。连续治疗6周后,比较两组患者的CIP评分、血清炎症因子水平、临床-影像-生理(CRP)评分、Karnofsky评分的变化。结果 治疗后,对照组CIP评分为(1.78±0.61),观察组(1.44±0.24),两组CIP评分下降,观察组较对照组评分下降有显著性差异(P<0.05); 两组CRP评分显著下降(P<0.05); 两组TNF-α、IL-1β水平较治疗前下降,观察组低于对照组(P<0.05),两组治疗后Karnofsky评分升高,观察组高于对照组(P<0.05)。结论 麻杏石甘汤联合甲泼尼龙治疗癌症患者免疫性肺炎的疗效优于单用甲泼尼龙,有助于调节免疫抑制状态,增强免疫功能,改善生活质量。

Abstract:

Objective Checkpoint inhibitor pneumonitis(CIP)is more prevalent in Asian populationswith extremely high lethal rate. In order to search for highly effective therapeutic alternatives, we observed the effect of Ma Xing Shi Gan decoction(MXD)combined with methylprednisolone on immune-related pneumonitis caused by PD-1 inhibitors in cancer patients. Methods Thirty-five cancer patients with immune-related pneumonitis were divided into two groups. Control group: methylprednisolone 18 cases, experimental group: Ma Xing Shi Gan decoction(MXD)combined with methylprednisolone 17 cases. Comparison was made on the difference of CIP score, serum inflammatory cytokines, CRP score and Karnofsky score after 6 consecutive weeks of treatment. Results After treatments, control group CIP is(1.78±0.61), experimental groupis(1.44±0.24). CIP scores decreased in both groups, and the experimentalgroup decreased significantly compared with the control group. CRP were significantly decreased in both groups(P<0.05)in both groups, while Karnofsky scorewas significantly increased(P<0.05)in both groups after treatments. Conclusion Combination therapy of Ma Xing Shi Gan decoction(MXD)plus methylprednisolone was more effective at treating immune-related pneumonitis than methylprednisolone monotherapy in cancer patients, which contributes to regulate immunosuppression state, enhance immune function and improve quality of life.

参考文献/References:

1 Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PDL1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8: 561.
2 Friedman CF, Proverbs-singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2(10): 1346-1353.
3 Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group[J]. JImmunother Cancer, 2017, 5(1): 95.
4 Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis,treatmentand follow-up[J]. Ann Oncol, 2017, 28(4): iv119-iv142.
5 Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768.
6 Nishino M, Ramaiya NH, AwadMM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016, 22(24): 6051-6060.
7 Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717.
8 Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J]. Eur Respir J, 2017, 50(2): 1700050.
9 Wang HP, Guo XX, Zhou JX, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor associated pneumonitis[J]. Thoracic Cancer, 2020, 11(1): 191-197.
10 Wang YS, Zhang QF, Chen YC, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine[J]. Biomed Pharmacother, 2019, 121: 109570.
11 陈 浪. 免疫检查点抑制剂联合中药治疗54例晚期恶性肿瘤不良反应的临床观察[D]. 安徽中医药大学, 2020.
12 Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis[J]. Cancer Manag Res, 2017, 9(1): 207-213.
13 陈 晨, 贾立群, 娄彦妮, 等. 免疫检查点抑制剂相关性肺炎发病及治疗的中医思考[J]. 中国中医急症, 2022, 31(3): 425-432.
14 Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423.
15 Pozzessere C, Bouchaab H, Jumeau R, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study[J]. ERJ Open Res, 2020, 6(1): 00165- 2019.
16 Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717.
17 Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study[J]. Cancer Med, 2018, 7(8): 4115-4120.
18 Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer[J]. Chest, 2021, 160(2): 731-742.
19 Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial[J]. J Thorac Oncol, 2016, 11(4): S115
20 Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(8): 1112-1115.
21 Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis[J]. J Clin Invest, 2019, 129(10): 4305-4315.
22 Johnson DB, Balko JM. Biomarkers for immunotherapy toxicity: are cytokines the answer?[J]. Clin Cancer Res, 2019, 25(5): 1452-1454.
23 Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy[J]. Clin Cancer Res, 2019, 25(5): 1557-1563.
24 Iwama S, De Remigis A, Callahan MK,et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J]. Sci Transl Med, 2014, 6(230): 230ra45.
25 张德珂, 聂金娥, 钱芳芳. 中药苦杏仁药理作用研究进展[J]. 山东化工, 2021, 50(22): 100-105.

备注/Memo

备注/Memo:

通信作者: 安 琦, Email: anqi_51_423@163.com

常用功能

更新日期/Last Update: 2022-12-20